Page last updated: 2024-09-05

lapatinib and Metastase

lapatinib has been researched along with Metastase in 130 studies

Research

Studies (130)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	26 (20.00)	29.6817
2010's	92 (70.77)	24.3611
2020's	12 (9.23)	2.80

Authors

Authors	Studies
Ansari, K; Bhan, A; Chen, MY; Jandial, R	1
Aydiner, A; Dogan, I; Ibis, K; Kizildag, I; Özkurt, S; Saip, P; Vatansever, S	1
Feng, J; Hu, X; Jiang, Z; Li, H; Li, W; Liu, Y; Ma, F; Ouyang, Q; Tong, Z; Wang, S; Xu, B; Yu, S; Zhu, X; Zou, J	1
Ali, AA; Alqhtani, H; Balkrishnan, R; de Lima Lopes, G; Diaby, V; Ko, Y; Palacio, S; van Boemmel-Wegmann, S; Wang, CY	1
Ge, R; Ji, X; Li, W; Luo, T; Sang, D; Wang, B; Xie, Y; Yuan, P	1
Fu, P; Fu, Z; Huang, X; Jiang, Z; Jin, F; Li, J; Li, W; Li, Y; Sun, C; Wang, B; Wang, H; Wang, J; Wu, H; Yan, M; Yang, F; Yang, M; Yin, Y; Zeng, T; Zhang, J	1
Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C	1
Ali, A; Ali, SM; Aparicio, S; Chen, BE; Cream, L; Drabick, J; Gelmon, K; Halstead, ES; Leitzel, K; Lipton, A; Maddukuri, A; Mckeone, D; Moku, P; Nagabhairu, V; Nomikos, D; Pancholy, N; Parulekar, WR; Polimera, H; Poulose, J; Shepherd, L; Spiegel, H; Umstead, TM; Virk, S; Zhu, L	1
Acosta, EP; Caterinicchia, V; Chen, D; Della Manna, DL; Falkson, CI; Forero-Torres, A; Li, Y; May, JE; Nabell, LM; Olariu, E; Rocque, GB; Stringer-Reasor, EM; Vaklavas, C; Yang, ES	1
Bick, G; Cai, C; Charif, M; Guan, JL; Hao, M; Leonard, M; Lower, EE; Luo, Z; Wang, J; Yang, Y; Yeo, S; Zhang, X	1
Bai, Y; Cheng, Y; Cui, Y; Duan, X; Liu, Q; Liu, Y; Qin, N; Xiang, Q; Xu, L; Zhang, J; Zhang, Z	1
Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y	1
Bradbury, P; Chia, SK; Eisenhauer, E; Ellard, SL; Gelmon, K; Goodwin, R; Hagerman, L; Kumar, V; Lohrisch, C; Mates, M; Mihalcioiu, C; Miller, WH; Sakashita, S; Taylor, S; Tsao, MS; Wang, T; Welch, S	1
Ali, SM; Aparicio, S; Carney, WP; Chapman, JW; Crescnzo, RJ; Ellis, CE; Gelmon, KA; Ho, D; Huang, J; Leitzel, K; Lipton, A; Nomikos, D; Parulekar, WR; Shepherd, L; Virk, S; Zhu, L	1
Badovinac-Crnjevic, T; Ferrero, JM; Hoersch, S; Kim, SB; Krop, IE; LoRusso, PM; Martin, AG; Smitt, M; Wildiers, H	1
Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S	1
Bagheri, N; Kosari, S; Madden, R; Peterson, GM; Thomas, J	1
Burki, TK	1
Chang, DY; Chao, TY; Chen, TW; Cheng, AL; Chow, LW; Consortium, TBC; Hsieh, YY; Huang, SM; Lin, CH; Lu, YS; Yeh, DC	1
Ding, C; Jiao, XD; Yu, G; Zang, YS	1
Arumí, M; Bellet, M; Escrivá-de-Romaní, S; Saura, C	1
Anders, CK; Copeland, AC	1
Barinoff, J; Bauerschlag, DO; Bischoff, J; Costa, SD; Gerber, B; Grischke, EM; Herr, D; Krabisch, P; Kümmel, S; Loibl, S; Lübbe, K; Maass, N; Marmé, F; Müller, V; Mundhenke, C; Nekljudova, V; Schmidt, M; Schumacher, C; Seiler, S; Thill, M; von Minckwitz, G	1
Baez-Vallecillo, L; Barcenas, CH; Hess, KR; Moulder, SL; Murthy, RK; Raghavendra, AS; Tripathy, D; Valero, V	1
Alvarez, R; Barcenas, CH; Booser, DJ; Brewster, AM; Brown, PH; Davis, DW; Giordano, SH; Ibrahim, NK; Iwase, T; Jackson, SA; Lee, J; Lim, B; Moscow, JA; Moulder, SL; Murthy, RK; Piekarz, R; Shen, Y; Tripathy, D; Ueno, NT; Valero, V; Willey, JS; Wu, J	1
Aguirre, E; Antón, A; Bermejo, B; Brunet, J; Ciruelos, E; Cortés, J; Cotes-Sanchís, A; De La Haba, J; García Sáenz, JÁ; Gavilá, J; Guerrero-Zotano, AL; Huerta, M; Lao Romera, J; Llombart-Cussac, A; Muñoz-Couselo, E; Rodríguez Sánchez, CA; Rodríguez-Lescure, Á; Ruiz-Borrego, M; Sánchez Rovira, P; Santaballa, A; Santisteban, M	1
Gwak, HS; Han, JM; Moon, JY; Seo, I	1
Antoniani, B; Botti, C; Ciccarese, M; Cognetti, F; Di Benedetto, A; Ercolani, C; Fabi, A; Ferretti, G; Gori, S; Malaguti, P; Marino, M; Merola, R; Mottolese, M; Nisticò, C; Papaldo, P; Sperduti, I; Vici, P	1
Ahmed, S; Ammannagari, N; Bravin, EN; Patel, A	1
Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W	1
Gradishar, WJ	1
Burris, HA; Crown, J; DeSilvio, M; Diéras, V; Espie, M; Kennedy, MJ; Koch, KM; Kothari, D; Lau, MR; Marty, M; Tresca, P	1
Gustafson, DL; Hudachek, SF	1
Arribas, J; Baselga, J; Caratù, G; De Mattos-Arruda, L; Felip, E; Grueso, J; Hernández-Losa, J; Nuciforo, P; Parra, JL; Prudkin, L; Puente, XS; Scaltriti, M; Seoane, J; Serra, V; Silberschmidt, D; Vivancos, A	1
Basaran, G; Benekli, M; Cetin, B; Eralp, Y; Isikdogan, A; Karaca, H; Kucukoner, M; Onur, H; Ozkan, M; Saip, P; Sen, F; Un, O	1
Barker, HE; Chang, J; Cox, TR; Erler, JT; Martens, JW; Nicolau, MM; Wetterskog, D	1
Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF	1
Fan, Y; Li, HH; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P	1
Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G	1
Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E	1
Bian, L; Du, G; Guo, YF; Jiang, ZF; Li, W; Song, ST; Wang, T; Wu, SK; Zhang, HQ; Zhang, SH	1
Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q	1
Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF	1
Inoue, T; Iyoda, T; Uetsuka, Y; Yamamoto, W	1
DeSilvio, M; Ellis, C; Guan, Z; Jiang, Z; Leigh, M; Russo, M; Shen, Z; Tong, Z; Xu, B; Yang, J	1
Awada, A; Bogaerts, J; Brain, E; Cardoso, F; Fumoleau, P; Hayward, L; Koch, KM; Lokiec, F; Marréaud, S; Rezai, K; Werutsky, G	1
Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK	1
He, J; Li, YS; Wei, X; Yu, FF; Zhang, TY; Zhang, X; Zhang, XJ	1
Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B	1
Shawky, H; Tawfik, H	1
Baron-Hay, S; Bauwens, A; Chan, A; Craft, P; de Boer, R; Kotasek, D; Redfern, A; Shannon, C; Townsend, A; Webb, S	1
Coussy, F; Cuvier, C; Espié, M; Giacchetti, S; Hocini, H; Teixeira, L	1
Kaneko, T; Lau, MR; Lunec, J; Margetts, J; Novello, S; Nutt, J; Plummer, R; Ramlau, R; Reck, M; Scagliotti, GV; Thomas, M	1
Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L	1
Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S	1
Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N	1
Al-Foheidi, M; Al-Rehaily, S; Darwish, T; Karim, SM; Mahrous, M; Mansour, M; Mokhtar, M; Rizvi, A; Zekri, J	1
Moser, A; Piwko, C; Pollex, E; Prady, C; Yunger, S	1
Arteaga, CL; Barry, WT; Dees, EC; Falkson, CI; Guo, H; Hobday, TJ; Krop, IE; Lin, NU; Mayer, IA; Najita, JS; Nanda, R; Richardson, AL; Rimawi, MF; Ryabin, N; Van den Abbeele, AD; Winer, EP; Wolff, AC; Yap, JT	1
Casanova, C; Dazzi, C; Mazza, V; Verlicchi, A	1
Alunni-Fabbroni, M; de Gregorio, N; Fehm, T; Friedl, TW; Hartkopf, A; Huober, J; Janni, W; Meier-Stiegen, F; Müller, V; Pantel, K; Rack, B; Schneeweiss, A; Schochter, F; Scholz, C; Schramm, A; Taran, FA; Trapp, E; Wallwiener, D	1
Bitterman, H; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A; Yerushalmi, R	1
Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M	1
Bian, L; Du, G; Guo, Y; Jiang, Z; Song, S; Wang, T; Xu, X; Zhang, S; Zhuo, J	1
Chen, X; Ding, L; Jin, L; Liang, GK; Wu, HH; Yao, ZT; Zhang, JQ	1
Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L	1
Griggs, JJ; Hayes, DF; Henry, NL; Kidwell, KM; Merajver, SD; Murthy, P; Schott, AF; Smerage, JD; Van Poznak, CH; Wicha, MS	1
Harvey, R; Simpson, E; Squires, H; Stevens, J; Stevenson, M	1
Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bertotti, A; Cassingena, A; Ciardiello, F; Comoglio, PM; Depetris, I; Ghezzi, S; Lauricella, C; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Palmeri, L; Racca, P; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Veronese, S; Zagonel, V	1
Bagley, S; Bauml, J; Cohen, RB; Hayes, DN; Hwang, WT; Langer, C; Olson, JG; Weiss, JM	1
Barni, S; Bisagni, G; Bogina, G; Duranti, S; Fabi, A; Fiorio, E; Foglietta, J; Gori, S; Inno, A; Leonardi, V; Lunardi, G; Marchetti, F; Montemurro, F; Pavese, I; Pellegrino, A; Rossi, V; Santini, D; Saracchini, S; Turazza, M; Vici, P; Zambelli, A	1
Buskens, E; de Bock, GH; Greuter, MJW; Koleva-Kolarova, RG; Oktora, MP; Reyners, AKL; Robijn, AL	1
Benowitz, S	1
Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M	1
Paul, B; Thompson, J; Trovato, JA	1
Spector, N	1
Halterman, PA	1
Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R	1
Arbushites, MC; Aziz, Z; Bines, J; Dering, J; Di Leo, A; Finn, RS; Gomez, HL; Guerrera, SF; Koehler, M; Oliva, C; Press, MF; Stein, SH; Williams, LS; Zvirbule, Z	1
Hay, JW; Le, QA	1
Arteaga, CL; Boimel, PJ; Coniglio, SJ; Hynes, NE; Kedrin, D; Segall, JE; Wyckoff, J	1
Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C	1
Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A	1
Wicha, MS	1
Amonkar, MM; Aziz, Z; Bines, J; Di Leo, A; Gomez, HL; Sherrill, B; Wu, Y; Zvirbule, Z	1
Amir, E; Clemons, M; Freedman, O; Ocaña, A; Seruga, B	1
Baselga, J; Bischoff, J; Blackwell, KL; Burstein, HJ; Casey, M; Ellis, C; Koehler, M; O'Shaughnessy, J; Rugo, H; Sledge, G; Storniolo, AM; Vukelja, S	1
Brandes, AA; Degli Esposti, R; Franceschi, E; Tosoni, A	1
Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L	1
Ferraz, MB; Puga, ME; Riera, R; Soárez, PC	1
Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ	1
Pownall, M	1
Curran, MP	1
Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I	1
Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL	1
de Weger, RA; Moelans, CB; van Diest, PJ	1
Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N	1
Morioka, T; Niikura, N; Okamura, T; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B	1
Amonkar, MM; Baselga, J; Blackwell, KL; Burstein, HJ; Ellis, C; O'Shaughnessy, J; Sherrill, BH; Wu, Y	1
Ali, SM; Carney, W; Gagnon, R; Leitzel, K; Lipton, A; Maltzman, J; Martin, AM; Platek, G; Steplewski, K; Westlund, R	1
Bignon, YJ; Cayre, A; El Guerrab, A; Nemlin, CC; Penault-Llorca, F; Rossignol, F; Vigier, F; Zegrour, R	1
Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W	1
Bisagni, G; Clavarezza, M; Cognetti, F; Crivellari, D; Fabi, A; Ferzi, A; Foglietta, J; Gamucci, T; Gori, S; Metro, G; Montemurro, F; Silva, RR; Spazzapan, S; Stocchi, L; Torrisi, E	1
Arbushites, MC; Chien, AJ; Dickler, MN; Franco, SX; Glencer, A; Hudis, C; Lahiri, S; Nulsen, B; Park, JW; Rugo, HS; Scott, J; Stopeck, AT	1
Carli, P; Crivellari, D; Di Lauro, V; Dolcetti, R; Lamaj, E; Miolo, G; Quitadamo, D; Spada, A; Spazzapan, S; Turchet, E; Veronesi, A	1
Bekaii-Saab, T; O'Neil, B; Peck, J; Villalona Calero, M; Wei, L; Zalupski, M	1
Beijnen, JH; Guchelaar, HJ; Opdam, FL; Schellens, JH	1
Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M	1
Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L	1
Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R	1
Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J	1
Deng, X; Erfani, SF; Hemler, ME; Hoff, J; Jin, H; Kaetzel, DM; Li, Q; Novak, M; Rabinovitz, I; Sharma, C; Sonnenberg, A; Stipp, CS; Yang, H; Yang, XH; Yi, Y; Zhou, P	1
Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G	1
Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M	1
Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M	1
Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A	1
Blackwell, KL; Burris, HA; Dees, EC; Dowlati, A; Ellis, MJ; Harris, JL; Hurwitz, HI; Jones, SF; Koch, KM; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A	1
Laurie, SA; Licitra, L	1
Boggess, KA; Dees, EC; Dorflinger, LJ; Graham, M; Harris, J; Humes, E; Kelly, H; O'Neil, BH; Spector, NL	1
Amar, S; Moreno-Aspitia, A; Perez, EA	1
Eniu, A	1
Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P	1
Doyle, DM; Miller, KD	1
Heinemann, V; Rack, B; Salat, C; Schindlbeck, C; Sommer, H; Walther, J	1
Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E	1
Dean-Colomb, W; Esteva, FJ	1
Ang, PC; Arbushites, MC; Aziz, Z; Berger, MS; Casey, MA; Chavez, MA; Chow, LW; Doval, DC; Franco, SX; Gomez, HL; Nag, S; Ng, C; Sledge, GW; Stein, SH	1
Amar, S; Perez, EA; Roy, V	1

Reviews

33 review(s) available for lapatinib and Metastase

Article	Year
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast cancer research and treatment, 2020, Volume: 183, Issue:1 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab	2020
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review . International journal of clinical pharmacology and therapeutics, 2018, Volume: 56, Issue:2 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Treatment Outcome	2018
HER2-positive breast cancer: Current and new therapeutic strategies. Breast (Edinburgh, Scotland), 2018, Volume: 39 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab	2018
Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going. Oncology (Williston Park, N.Y.), 2018, Oct-15, Volume: 32, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Lapatinib; Mastectomy; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab	2018
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:10 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
[Clinical evaluation of lapatinib therapy in metastatic breast cancer using the Bayes meta-analysis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:3 Topics: Antineoplastic Agents; Bayes Theorem; Breast Neoplasms; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome	2014
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:11 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2014
Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review. BMC cancer, 2014, Aug-28, Volume: 14 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2014
[New targeted therapies in breast cancer]. Gynecologie, obstetrique & fertilite, 2014, Volume: 42, Issue:11 Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab	2014
HER2-positive metastatic breast cancer: a changing scenario. Critical reviews in oncology/hematology, 2015, Volume: 95, Issue:1 Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2015
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2016, Volume: 34, Issue:7 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab	2016
Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer treatment reviews, 2017, Volume: 55 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Lapatinib; Life Expectancy; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab	2017
Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Sep-15, Volume: 65, Issue:18 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Food-Drug Interactions; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2008
Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab. Clinical breast cancer, 2008, Volume: 8 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2008
Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Pharmacotherapy, 2008, Volume: 28, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epothilones; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines	2008
Lapatinib for the treatment of HER2-overexpressing breast cancer. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2	2009
Lapatinib in metastatic breast cancer. Women's health (London, England), 2009, Volume: 5, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab	2009
Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer treatment reviews, 2010, Volume: 36, Issue:5 Topics: Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2010
Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert review of anticancer therapy, 2010, Volume: 10, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab	2010
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. Sao Paulo medical journal = Revista paulista de medicina, 2009, Volume: 127, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic	2009
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. Drugs, 2010, Jul-30, Volume: 70, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles	2010
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:6 Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles	2011
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2011
Target therapy in elderly breast cancer patients. Critical reviews in oncology/hematology, 2012, Volume: 83, Issue:3 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A	2012
Lapatinib for advanced or metastatic breast cancer. The oncologist, 2012, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines	2012
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Current medical research and opinion, 2012, Volume: 28, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles	2012
Systemic therapy in the palliative management of advanced salivary gland cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab	2006
Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast cancer research and treatment, 2008, Volume: 109, Issue:1 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Lapatinib; Medical Oncology; Models, Biological; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab	2008
Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2007, Volume: 12 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Heart Diseases; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A	2007
[Metastatic breast cancer--new methods of treatment]. MMW Fortschritte der Medizin, 2008, Jan-17, Volume: 150, Issue:1-2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Histocytochemistry; Humans; Lapatinib; Neoplasm Metastasis; Osteonecrosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Trastuzumab	2008
Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert review of anticancer therapy, 2008, Volume: 8, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab	2008
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Seminars in oncology, 2008, Volume: 35, Issue:2 Suppl 2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine	2008
Treatment of metastatic breast cancer: looking towards the future. Breast cancer research and treatment, 2009, Volume: 114, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome	2009

Trials

39 trial(s) available for lapatinib and Metastase

Article	Year
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-10, Volume: 37, Issue:29 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrrolidines; Receptor, ErbB-2; Taxoids; Trastuzumab	2019
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast cancer research : BCR, 2021, 03-04, Volume: 23, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Disease Management; Drug Monitoring; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Treatment Outcome; Triple Negative Breast Neoplasms	2021
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast cancer research : BCR, 2017, 05-02, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-1	2017
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast cancer research and treatment, 2017, Volume: 164, Issue:3 Topics: Adult; Aged; Antigens, Neoplasm; Breast Neoplasms; Carbonic Anhydrase IX; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Trastuzumab; Treatment Outcome; Young Adult	2017
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:6 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Early Termination of Clinical Trials; Female; Hemorrhage; Humans; Lapatinib; Male; Maytansine; Middle Aged; Neoplasm Metastasis; Neutropenia; Practice Patterns, Physicians'; Quinazolines; Receptor, ErbB-2; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab	2017
Improved progression-free survival in metastatic breast cancer. The Lancet. Oncology, 2018, Volume: 19, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Progression-Free Survival; Quality Improvement; Receptor, ErbB-2; Trastuzumab; United Kingdom	2018
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Japanese journal of clinical oncology, 2018, Mar-01, Volume: 48, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Demography; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Vinblastine; Vinorelbine	2018
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-cancer drugs, 2019, Volume: 30, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Furans; Humans; Ketones; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab	2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. British journal of cancer, 2019, Volume: 120, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Breast Neoplasms, Male; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Pyridines; Receptor, ErbB-2; Survival Rate; Trastuzumab	2019
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. The oncologist, 2013, Volume: 18, Issue:6 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Young Adult	2013
Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Time Factors; Turkey; Vinblastine; Vinorelbine	2013
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast cancer research and treatment, 2014, Volume: 143, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine	2014
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:5 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome	2014
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome	2014
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-10, Volume: 32, Issue:32 Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome	2014
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study. Journal of the Egyptian National Cancer Institute, 2014, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2014
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; Vinblastine; Vinorelbine	2014
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. Clinical lung cancer, 2015, Volume: 16, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Thymidylate Synthase; Treatment Outcome	2015
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. International journal of clinical oncology, 2015, Volume: 20, Issue:6 Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate	2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-20, Volume: 33, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2015
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Archives of gynecology and obstetrics, 2016, Volume: 293, Issue:2 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Phenotype; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab	2016
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. British journal of cancer, 2008, Sep-02, Volume: 99, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis	2008
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. The oncologist, 2008, Volume: 13, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult	2008
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Placebos; Quinazolines; Receptor, ErbB-2; Retrospective Studies	2008
Lapatinib for the treatment of HER2-overexpressing breast cancer. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2	2009
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current medical research and opinion, 2010, Volume: 26, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Lapatinib; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quinazolines; Receptor, ErbB-2	2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-01, Volume: 28, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Function, Left	2010
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome	2010
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:12 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires; Trastuzumab; Treatment Outcome	2011
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 134, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2012
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology, 2012, Volume: 82, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate	2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-10, Volume: 30, Issue:26 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PloS one, 2012, Volume: 7, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab	2012
Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine, 2012, Nov-08, Volume: 367, Issue:19 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult	2012
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-10, Volume: 23, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Quinazolines; Receptor, ErbB-2; Safety; Treatment Outcome	2005
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast cancer research and treatment, 2008, Volume: 112, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab	2008
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-20, Volume: 26, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2008

Other Studies

59 other study(ies) available for lapatinib and Metastase

Article	Year
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain. Scientific reports, 2021, 10-15, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Carriers; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2	2021
Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process. Oncology, 2023, Volume: 101, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Trastuzumab	2023
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast (Edinburgh, Scotland), 2020, Volume: 49 Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Middle Aged; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Taiwan; Trastuzumab	2020
Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study. Cancer medicine, 2020, Volume: 9, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab	2020
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population. BMC cancer, 2020, Mar-29, Volume: 20, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab	2020
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial. Cancer, 2020, 11-15, Volume: 126, Issue:22 Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Metastasis; Progression-Free Survival; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Trastuzumab	2020
Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer. Cell reports, 2021, 03-09, Volume: 34, Issue:10 Topics: Animals; Antineoplastic Agents; Cell Movement; COP9 Signalosome Complex; Epithelial-Mesenchymal Transition; Female; Genetic Vectors; Lapatinib; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mediator Complex Subunit 1; Mice; Mice, Nude; Neoplasm Metastasis; Neoplastic Stem Cells; Peptide Hydrolases; Phenotype; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Transcriptional Activation	2021
Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient. Thoracic cancer, 2021, Volume: 12, Issue:12 Topics: Breast Neoplasms; Cholangitis, Sclerosing; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Vinorelbine	2021
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy. JCI insight, 2021, 09-22, Volume: 6, Issue:18 Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation	2021
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology, 2017, Nov-09, Volume: 3, Issue:11 Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome	2017
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. BMC cancer, 2018, 02-20, Volume: 18, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Capecitabine; Diagnostic Imaging; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Meningeal Carcinomatosis; Multimodal Imaging; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome	2018
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast cancer research and treatment, 2019, Volume: 176, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome; Young Adult	2019
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Spain; Trastuzumab; Treatment Outcome	2020
Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. Breast cancer research and treatment, 2019, Volume: 178, Issue:1 Topics: Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A Inducers; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Incidence; Lapatinib; Multivariate Analysis; Neoplasm Metastasis; Retrospective Studies; Risk Factors	2019
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Dosage; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Regression Analysis; ROC Curve	2013
Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:9 Topics: Brain Neoplasms; Female; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2013
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice. Anti-cancer drugs, 2013, Volume: 24, Issue:9 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Intestine, Small; Lapatinib; Membrane Transport Modulators; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Quinazolines; Taxoids; Tissue Distribution; Topoisomerase II Inhibitors; Tubulin Modulators	2013
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer discovery, 2013, Volume: 3, Issue:11 Topics: Adult; Exome; Female; Humans; Lapatinib; Li-Fraumeni Syndrome; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured	2013
LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling. Breast cancer research : BCR, 2013, Volume: 15, Issue:4 Topics: Acinar Cells; Amino Acid Oxidoreductases; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Morphogenesis; Neoplasm Metastasis; Phenotype; Prognosis; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Signal Transduction	2013
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Feb-01, Volume: 20, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles	2014
[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:7 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab	2013
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate	2014
Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab. Cancer biology & therapy, 2014, Volume: 15, Issue:4 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult	2014
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult	2014
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib Breast cancer research : BCR, 2014, Jul-24, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Metastasis; Odds Ratio; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2014
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Retreatment; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult	2015
Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer. Experimental oncology, 2015, Volume: 37, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Young Adult	2015
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. Clinical drug investigation, 2015, Volume: 35, Issue:8 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Canada; Capecitabine; Delivery of Health Care; Female; Health Care Costs; Humans; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab	2015
Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report. Future oncology (London, England), 2015, Volume: 11, Issue:15 Suppl Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Fatal Outcome; Female; Furans; Humans; Ketones; Lapatinib; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab	2015
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study. PloS one, 2015, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Israel; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab	2015
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nature communications, 2015, Nov-04, Volume: 6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab	2015
[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance]. Zhonghua yi xue za zhi, 2015, Jul-28, Volume: 95, Issue:28 Topics: Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Lapatinib; Neoplasm Metastasis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2015
[Combination of lapatinib with chlorogenic acid inhibits breast cancer metastasis by suppressing macrophage M2 polarization]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2015, Volume: 44, Issue:5 Topics: Animals; Chlorogenic Acid; Female; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Quinazolines	2015
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. Journal of medical economics, 2016, Volume: 19, Issue:6 Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles	2016
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast cancer research and treatment, 2016, Volume: 155, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Trastuzumab	2016
Colorectal Cancer Yields to Dual HER2 Blockade. Cancer discovery, 2016, Volume: 6, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Humans; Lapatinib; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2016
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer, 2016, 08-01, Volume: 122, Issue:15 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Italy; Lapatinib; Logistic Models; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult	2016
As metastasis yields its biological secrets, researchers hope to apply findings. Journal of the National Cancer Institute, 2008, Aug-06, Volume: 100, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab	2008
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer, 2009, Feb-01, Volume: 115, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity	2009
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11 Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Movement; ErbB Receptors; Female; Gefitinib; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays	2009
Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working? Oncology (Williston Park, N.Y.), 2009, Volume: 23, Issue:11 Suppl N Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab	2009
Targeting breast cancer stem cells. Breast (Edinburgh, Scotland), 2009, Volume: 18 Suppl 3 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Isoenzymes; Lapatinib; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Retinal Dehydrogenase; Signal Transduction	2009
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-15, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome	2010
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy. BMJ (Clinical research ed.), 2010, Jun-11, Volume: 340 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom	2010
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer biology & therapy, 2010, Nov-01, Volume: 10, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2010
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Dec-15, Volume: 16, Issue:24 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chromosomes, Human, Pair 17; Female; Gene Amplification; Humans; Lapatinib; Neoplasm Metastasis; Polyploidy; Prognosis; Quinazolines; Receptor, ErbB-2	2010
Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer. The Tokai journal of experimental and clinical medicine, 2010, Dec-20, Volume: 35, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure	2010
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer, 2011, Nov-01, Volume: 117, Issue:21 Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2011
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PloS one, 2011, Volume: 6, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cetuximab; DNA; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Reporter; Green Fluorescent Proteins; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Lapatinib; Molecular Sequence Data; Neoplasm Metastasis; Quinazolines; Transcription, Genetic	2011
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome	2012
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Failure	2012
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Molecular oncology, 2012, Volume: 6, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome	2012
Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:8 Topics: Animals; Butadienes; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; Female; Focal Adhesion Kinase 1; Humans; Integrin alpha6beta4; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tetraspanin 24; Transendothelial and Transepithelial Migration	2012
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. Journal of medical economics, 2013, Volume: 16, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series. Anticancer research, 2012, Volume: 32, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms	2012
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies	2012
Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clinical breast cancer, 2006, Volume: 7, Issue:4 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Infant, Newborn; Lapatinib; Live Birth; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines	2006
Development of new targeted therapies for breast cancer. Breast cancer (Tokyo, Japan), 2008, Volume: 15, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Female; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Trastuzumab	2008